Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Cash from Financing Activities (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Cash from Financing Activities data on record, last reported at $6950.0 in Q3 2025.

  • For Q3 2025, Cash from Financing Activities fell 99.99% year-over-year to $6950.0; the TTM value through Sep 2025 reached $81.2 million, down 14.43%, while the annual FY2024 figure was $152.8 million, 497.23% up from the prior year.
  • Cash from Financing Activities reached $6950.0 in Q3 2025 per CAPR's latest filing, down from $19580.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $81.1 million in Q4 2024 and bottomed at $3895.0 in Q1 2023.
  • Average Cash from Financing Activities over 5 years is $10.7 million, with a median of $1.9 million recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: surged 58699.59% in 2024, then plummeted 99.99% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $42370.0 in 2021, then skyrocketed by 6861.35% to $2.9 million in 2022, then skyrocketed by 685.45% to $23.2 million in 2023, then soared by 250.01% to $81.1 million in 2024, then crashed by 99.99% to $6950.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $6950.0 in Q3 2025, $19580.0 in Q2 2025, and $50354.0 in Q1 2025.